# Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)

Study · id `cardio:ct-nct02024230` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02024230](<https://clinicaltrials.gov/study/NCT02024230>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02024230

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

## Technical summary

Registry record NCT02024230. Non-randomized; no masking; primary purpose treatment. Start 2014-01 (actual); primary completion 2018-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (enrolled count; ClinicalTrials.gov record NCT02024230, source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)
- Started: 2014-01 (actual) (ClinicalTrials.gov record NCT02024230, source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)
- Primary completion: 2018-12 (actual) (ClinicalTrials.gov record NCT02024230, source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)
- Completion: 2022-12 (actual) (ClinicalTrials.gov record NCT02024230, source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02024230, source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02024230-2023-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)
- Acronym: REWRAPS
- Condition: Coronary Artery Disease
- Condition: Atrial Fibrillation
- Condition: Stroke
- Condition: Fetal Blood Loss
- Condition: Major Bleeding
- Condition: All Cause Mortality
- Intervention (Drug): Rivaroxaban or Warfarin
- Lead sponsor: Fujita Health University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 5720972bc5af9d0ee7eea4411d2b26e1e6b81138a8c083f6f4c17f81e50f0cff
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
